MARKET

MGEN

MGEN

Miragen Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.285
+0.315
+32.51%
Opening 15:18 01/27 EST
OPEN
1.080
PREV CLOSE
0.9700
HIGH
1.360
LOW
1.020
VOLUME
8.87M
TURNOVER
--
52 WEEK HIGH
3.800
52 WEEK LOW
0.4400
MARKET CAP
42.09M
P/E (TTM)
-0.9456
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MGEN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MGEN News

  • The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes
  • Benzinga.1d ago
  • miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences
  • GlobeNewswire.4d ago
  • The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering
  • Benzinga.12/20/2019 13:12
  • The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data
  • Benzinga.12/18/2019 12:23

More

Industry

Biotechnology & Medical Research
-0.72%
Pharmaceuticals & Medical Research
-0.30%

Hot Stocks

Name
Price
%Change

About MGEN

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.
More

Webull offers Miragen Therapeutics Inc (MGEN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.